Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 75

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 9B
Chunk 75
---
 number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the ESPP by 405,547 shares. If purchase rights granted under the ESPP terminate without having been exercised, the shares of our common stock not purchased under such purchase rights will again become available for issuance under the ESPP.As of December 31, 2024, no shares of common stock were purchased under the ESPP. As of December 31, 2024, there was an aggregate of 1,247,861 shares reserved for future issuance under the ESPP.Stock Option ValuationThe weighted-average assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December 31, 2024, 2023, and 2022 were as follows:YEAR ENDED DECEMBER 31,202420232022Risk-free interest rate4.30 %3.96 %2.24 %Expected term (in years)5.916.056.06Expected volatility81.92 %81.34 %83.03 %Expected dividend yield0.00 %0.00 %0.00 %A summary of option activity during the year ended December 31, 2024 is as follows (in thousands except share and per share data):NUMBER OFOPTIONSWEIGHTED-AVERAGEEXERCISE PRICEWEIGHTED-AVERAGEREMAININGCONTRACTUALTERM (IN YEARS)AGGREGATEINTRINSIC VALUEOutstanding as of January 1, 20244,394,807 $36.08 7.31$46,319 Granted1,643,300 57.07 Exercised(398,525)30.47 $10,126 Cancelled or forfeited(227,762)50.47 Expired(27,060)56.52 Outstanding as of December 31, 20245,384,760 $42.19 7.18$7,395 Options exercisable as of December 31, 20242,903,204 $32.52 5.90$7,395 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices